Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business6 October 2016Corporate and M&ADeal watch Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryUS firms top UK and global rankings in record year for M&A megadealsRevolving Doors: Quinn poaches Milbank partner as S&C adds to City structured finance teamLinklaters chief leads legal figures recognised in New Year Honours ListUS firms top UK and global rankings in record year for M&A megadealsTop US pair advise as Bridgepoint agrees to acquire KPMG spin-off InterpathHot markets and mega-deals: M&A partners on 2025 trends and hopes for the new yearDealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealDealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanDeal Watch: activity powers on as Latham and A&O lead on $19bn energy joint venture